article thumbnail

Pfizer, after delay, completes enrollment in Lyme vaccine trial

Bio Pharma Dive

The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.

Trials 278
article thumbnail

MinervaX raises $57m for Phase III trial of maternal strep vaccine

Pharmaceutical Technology

MinervaX is currently conducting Phase II trials of the prophylactic maternal vaccine against group B streptococcus bacterial infections.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK sets high bar with trial results for RSV vaccine

Bio Pharma Dive

With data expected for several other vaccines for the respiratory disease, GSK reported positive clinical trial results showing efficacy above 80%.

article thumbnail

Successful clinical trial for re-engineered Covid vaccine 

Drug Discovery World

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The Clamp2 trial group showed a 2.5-fold fold boost in neutralising ‘titres’ and it was 2.1 in the Novavax group.

article thumbnail

Moderna, in bid for transparency, discloses detailed plan of coronavirus vaccine trial

Bio Pharma Dive

The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its large Phase 3 trial.

article thumbnail

Gates, Wellcome-backed TB vaccine starts phase 3 trial

pharmaphorum

A highly anticipated phase 3 trial of a new tuberculosis vaccine developed by GSK has started in Africa, funded by the Gates MRI and Wellcome.

article thumbnail

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%